Etidocaine

Cat. No.: HY-B2080

CAS No.: 36637-18-0

Molecular Formula: $C_{17}H_{28}N_2O$

Molecular Weight: 276.42

Target: Others

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Etidocaine (EDC) is a long aminoamide local anesthetic[1].

In Vitro

IGL-EDC formulations can induce a significant increase in human fibroblasts survival[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	Human fibroblasts cells
Concentration:	0, 4, 8, 16, 24 mM
Incubation Time:	4, 6 and 24 h
Result:	Showed that cell survival decreased in a (EDC) concentration with time-dependent manner.

In Vivo

Etidocaine (spinal injection, 0.0075%, once) does not show postinjection neurologic deficit[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult Swiss Webster male mice[2]
Dosage:	0.0075%
Administration:	Etidocaine (spinal injection, 0.0075%, once)
Result:	Did not show postinjection neurologic deficit.

CUSTOMER VALIDATION

- bioRxiv. 2024 Apr 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Oliveira, et al. Sustained Release from Ionic-Gradient Liposomes Significantly Decreases ETIDOCAINE Cytotoxicity. Pharmaceutical research vol. 35, 12 229. 10 Oct. 2018.

[2]. Langerman, L, et al. The partition coefficient as a predictor of local anesthetic potency for spinal anesthesia: evaluation of five local anesthetics in a mouse model. Anesthesia and analgesia vol. 79,3 (1994): 490-4.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA